Muhammad Alam, MD
Psychiatry · Moultrie, GANPI 1750558979
Payments from drug & device makers
Across 37 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$235
- AbbVie$134
- E.r. Squibb & Sons, L.L.C.$108
- Alkermes, Inc.$90
- Teva Pharmaceuticals USA, Inc.$55
- Neurocrine Biosciences, Inc.$47
- plus $61 from 2 others
What the payments were for
- Food & beverage$730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $235 |
| AbbVie | 5 | $134 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| Alkermes, Inc. | 3 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
How this compares
$730 in reported general payments places this provider in the 60th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 308 | $2,948 |
| Hydroxyzine Pamoate | 245 | $2,388 |
| Atomoxetine Hcl | 33 | $2,292 |
| Aripiprazole | 62 | $2,047 |
| Duloxetine Hcl | 133 | $1,911 |
| Trazodone Hcl | 255 | $1,812 |
| Acamprosate Calcium | 17 | $1,555 |
| Naltrexone Hcl | 54 | $1,451 |
| Paliperidone ErPaliperidone | 16 | $1,437 |
| Olanzapine OdtOlanzapine | 25 | $1,402 |
| Oxcarbazepine | 46 | $1,152 |
| Buspirone Hcl | 103 | $1,101 |
| Bupropion XlBupropion Hcl | 80 | $987 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $890 |
| Mirtazapine | 92 | $859 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Moultrie
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.